Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00400231
Status:
COMPLETED
Last Update Posted:
2017-03-20
First Post:
2006-11-09
Brief Title:
The Fenofibrate and Metformin for Atherogenic Dyslipidemia FAMA Study
Sponsor:
University of Pennsylvania
Organization:
University of Pennsylvania
Study Overview
Official Title:
The Fenofibrate and Metformin for Atherogenic Dyslipidemia FAMA Study
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with metabolic syndrome insulin resistance and elevated triglycerides of 150 mgdl or higher will be randomized to one of four groups 1 placebo 2 metformin 3 fenofibrate or 4 combined metformin and fenofibrate for a period of 12 weeks after titration to target dose We are interested in the effects of these therapies on triglyceride levels HDL-C insulin resistance and markers of inflammation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None